Novavax Starts Phase 2 Coronavirus Vaccine Clinical Trial

Novavax (NASDAQ: NVAX) is behind the leaders in the race to develop a coronavirus vaccine to prevent COVID-19, but the biotech continues to trot along. On the heels of positive phase 1 data earlier this month, the biotech started the phase 2 portion of its phase 1/2 clinical trial testing its coronavirus vaccine NVX-CoV2373.

The new study will enroll up to 1,500 subjects, substantially more than the 131 subjects enrolled in the phase 1 study. The phase 2 portion also expands the potential ages of participants from a range of 18 to 59 in phase 1 to a range of 18 to 84 for the phase 2 study.

Since older adults are especially vulnerable if they catch COVID-19, its important for a vaccine to be both safe and able to generate an immune response in the older adults. To get the answer quickly, Novavax plans to enroll half of the clinical trial with older adults, aged 60 to 84.

Continue reading

Source Fool.com